877 related articles for article (PubMed ID: 9503565)
1. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
2. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
Knoll J
J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
[TBL] [Abstract][Full Text] [Related]
3. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
4. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
Knoll J
J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
[TBL] [Abstract][Full Text] [Related]
5. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
6. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases.
Knoll J
Med Res Rev; 1992 Sep; 12(5):505-24. PubMed ID: 1513186
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
Knoll J
Pharmacol Toxicol; 1992 May; 70(5 Pt 1):317-21. PubMed ID: 1608919
[TBL] [Abstract][Full Text] [Related]
9. [Medicamentous strategy for improving the quality of life in the senescence].
Knoll J
Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of (-)deprenyl.
Knoll J
J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
[TBL] [Abstract][Full Text] [Related]
11. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
12. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
Knoll J
J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
[TBL] [Abstract][Full Text] [Related]
13. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
14. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
15. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
16. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
17. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
Demarest KT; Smith DJ; Azzaro AJ
J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
[TBL] [Abstract][Full Text] [Related]
18. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
19. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
20. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
